Logo image of ABVX

ABIVAX SA-ADR (ABVX) Stock Fundamental Analysis

NASDAQ:ABVX - Nasdaq - US00370M1036 - ADR - Currency: USD

7.19  +0.28 (+4.05%)

Fundamental Rating

1

ABVX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. ABVX has a bad profitability rating. Also its financial health evaluation is rather negative. ABVX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ABVX had negative earnings in the past year.
In the past year ABVX has reported a negative cash flow from operations.
In the past 5 years ABVX always reported negative net income.
In the past 5 years ABVX always reported negative operating cash flow.
ABVX Yearly Net Income VS EBIT VS OCF VS FCFABVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of ABVX (-85.88%) is worse than 71.43% of its industry peers.
The Return On Equity of ABVX (-434.26%) is worse than 77.95% of its industry peers.
Industry RankSector Rank
ROA -85.88%
ROE -434.26%
ROIC N/A
ROA(3y)-74.48%
ROA(5y)-62.72%
ROE(3y)-493.52%
ROE(5y)-485.85%
ROIC(3y)N/A
ROIC(5y)N/A
ABVX Yearly ROA, ROE, ROICABVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

ABVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABVX Yearly Profit, Operating, Gross MarginsABVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

ABVX has more shares outstanding than it did 1 year ago.
ABVX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ABVX is higher compared to a year ago.
ABVX Yearly Shares OutstandingABVX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABVX Yearly Total Debt VS Total AssetsABVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -3.86, we must say that ABVX is in the distress zone and has some risk of bankruptcy.
ABVX has a Altman-Z score (-3.86) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.29 is on the high side and indicates that ABVX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.29, ABVX is not doing good in the industry: 79.54% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Altman-Z -3.86
ROIC/WACCN/A
WACCN/A
ABVX Yearly LT Debt VS Equity VS FCFABVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 1.82 indicates that ABVX should not have too much problems paying its short term obligations.
ABVX has a Current ratio of 1.82. This is in the lower half of the industry: ABVX underperforms 77.60% of its industry peers.
ABVX has a Quick Ratio of 1.82. This is a normal value and indicates that ABVX is financially healthy and should not expect problems in meeting its short term obligations.
ABVX has a worse Quick ratio (1.82) than 76.01% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.82
ABVX Yearly Current Assets VS Current LiabilitesABVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.74% over the past year.
EPS 1Y (TTM)16.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 32.90% on average over the next years. This is a very strong growth
ABVX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 135.66% yearly.
EPS Next Y-4.62%
EPS Next 2Y24.86%
EPS Next 3Y27.61%
EPS Next 5Y32.9%
Revenue Next Year588.98%
Revenue Next 2Y-12.67%
Revenue Next 3Y163.09%
Revenue Next 5Y135.66%

3.3 Evolution

ABVX Yearly Revenue VS EstimatesABVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ABVX Yearly EPS VS EstimatesABVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABVX. In the last year negative earnings were reported.
Also next year ABVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVX Price Earnings VS Forward Price EarningsABVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVX Per share dataABVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

ABVX's earnings are expected to grow with 27.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.86%
EPS Next 3Y27.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABIVAX SA-ADR

NASDAQ:ABVX (5/2/2025, 8:00:00 PM)

7.19

+0.28 (+4.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-24 2025-03-24/dmh
Earnings (Next)06-02 2025-06-02
Inst Owners41.83%
Inst Owner Change0.05%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap455.98M
Analysts87.69
Price Target36.55 (408.34%)
Short Float %2.73%
Short Ratio7.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)18.14%
PT rev (3m)28.42%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-9.94%
EPS NY rev (3m)-14.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-18.48%
Revenue NY rev (3m)-18.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.91
P/tB 25.84
EV/EBITDA N/A
EPS(TTM)-3.16
EYN/A
EPS(NY)-3.14
Fwd EYN/A
FCF(TTM)-2.77
FCFYN/A
OCF(TTM)-2.76
OCFYN/A
SpS0
BVpS0.73
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.88%
ROE -434.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.48%
ROA(5y)-62.72%
ROE(3y)-493.52%
ROE(5y)-485.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.82
Altman-Z -3.86
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1894.89%
Cap/Depr(5y)1415.08%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.47%
EPS Next Y-4.62%
EPS Next 2Y24.86%
EPS Next 3Y27.61%
EPS Next 5Y32.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year588.98%
Revenue Next 2Y-12.67%
Revenue Next 3Y163.09%
Revenue Next 5Y135.66%
EBIT growth 1Y-35.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.9%
EBIT Next 3Y29.55%
EBIT Next 5Y40.7%
FCF growth 1Y-58.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.62%
OCF growth 3YN/A
OCF growth 5YN/A